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INTRODUCTION
Point-of-care testing (POCT) for infections 
is being promoted to reduce antimicrobial 
resistance and improve patient outcomes.1 
POCT is frequently subject to evaluations 
of analytic performance, but is often 
introduced into practice without rigorous 
trials evaluating clinical and cost-
effectiveness.2–5
Approximately 10% of adult females 
experience a urinary tract infection (UTI) in 
any given year, and around half experience 
a UTI at some point in their lives.6 Around 
15–20% of the antibiotics prescribed in 
primary care are prescribed for UTI,7–9 but 
up to 60% of females with uncomplicated 
UTI who are treated with antibiotics do not 
have a positive urine culture.10–13 In addition, 
although antibiotics shorten the duration of 
symptoms on average, not all individuals 
benefit from antibiotic treatment;14,15 
furthermore, some females with a positive 
urine laboratory culture are not prescribed 
antibiotics.10 Better-targeted antibiotic 
prescribing may reduce unnecessary risk 
of side effects and subsequent infections 
that are antibiotic resistant, and, in so doing, 
may reduce symptom duration and the 
burden on health services in the future.16–18
Current strategies to predict 
microbiologically confirmed UTI in adult 
females need to be improved so that: 
• more females who will benefit from 
antibiotic treatment are prescribed 
antibiotics;
• antibiotic treatment is better targeted to 
the sensitivity of the infecting organisms; 
and 
• antibiotics are prescribed less often for 
females who will not benefit from them. 
Better-targeted antibiotic use is important 
for antibiotic stewardship, as antibiotic 
use drives resistance. There is, therefore, 
an urgent need to support clinicians in 
the community in deciding whether to 
prescribe antibiotics and in selecting the 
most appropriate antibiotic when indicated. 
POCT urine culture has been proposed 
as a solution in primary care because 
results can be available within 24 hours.19,20 
The approach is already widely used in 
Denmark, but has never been evaluated 
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Background
The effectiveness of using point-of-care (POC) 
urine culture in primary care on appropriate 
antibiotic use is unknown.
Aim
To assess whether use of the Flexicult™ SSI-
Urinary Kit, which quantifies bacterial growth 
and determines antibiotic susceptibility at the 
point of care, achieves antibiotic use that is more 
often concordant with laboratory culture results, 
when compared with standard care.
Design and setting
Individually randomised trial of females with 
uncomplicated urinary tract infection (UTI) in 
primary care research networks (PCRNs) in 
England, the Netherlands, Spain, and Wales.
Method
Multilevel regression compared outcomes 
between the two groups while controlling for 
clustering.
Results
In total, 329 participants were randomised to 
POC testing (POCT) and 325 to standard care, 
and 324 and 319 analysed. Fewer females 
randomised to the POCT arm than those 
who received standard care were prescribed 
antibiotics at the initial consultation (267/324 
[82.4%] versus 282/319 [88.4%], odds ratio 
[OR] 0.56, 95% confidence interval [CI] = 0.35 
to 0.88). Clinicians indicated the POCT result 
changed their management for 190/301 (63.1%). 
Despite this, there was no statistically significant 
difference between study arms in antibiotic use 
that was concordant with laboratory culture 
results (primary outcome) at day 3 (39.3% POCT 
versus 44.1% standard care, OR 0.84, 95% 
CI = 0.58 to 1.20), and there was no evidence of 
any differences in recovery, patient enablement, 
UTI recurrences, re-consultation, antibiotic 
resistance, and hospitalisations at follow-up. 
POCT culture was not cost-effective.
Conclusion
Point-of-care urine culture was not effective 
when used mainly to adjust immediate antibiotic 
prescriptions. Further research should evaluate 
use of the test to guide initiation of ‘delayed 
antibiotics’.
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in a rigorous randomised controlled trial 
to determine whether it benefits patients. 
Therefore, the authors aimed to determine 
the clinical effects and costs of POCT urine 
culture for symptoms of uncomplicated UTI 
on the overall appropriateness of antibiotic 
prescribing compared with current best 
practice.
METHOD
The POCT for UTI in primary care trial was 
a pragmatic, parallel, two-arm, individually 
randomised, open, test-treatment4 
controlled trial. It aimed to assess the 
costs and effects of an optimised POCT-
guided diagnostic and treatment strategy 
for symptoms of uncomplicated UTI in adult 
females on the overall appropriateness of 
antibiotic use when compared with practice 
based on best available local guidelines 
(standard care). This multinational trial 
was implemented in primary care research 
networks (PCRNs) in four countries — 
in England, the Netherlands, Spain, and 
Wales — which were selected based on 
past research experience and variation in 
resistance rates and usual management 
of UTI. 
The full POETIC protocol has been 
published elsewhere.21 A brief summary of 
trial procedures is presented below.
Participants
Network coordinators invited clinicians 
(GPs or nurse prescribers) in four PCRNs 
to take part. Participating clinicians 
identified eligible patients during routine 
general practice consultations. Females 
(aged ≥18 years) were eligible if they were 
presenting in primary care with at least 
one symptom of dysuria, urgency, or 
frequency, and had a clinical diagnosis of 
uncomplicated UTI. Females were excluded 
if they:
• had suspected pyelonephritis;
• were on long-term antibiotic treatment;
• had received antibiotics for UTI in the 
preceding 4 weeks; or 
• had significant genitourinary tract 
abnormalities or terminal illness. 
Patients were randomised before any 
dipstick testing and management decisions 
were made. There was no minimum 
recruitment target for clinicians.
Randomisation
Remote, online randomisation was stratified 
by practice, and used minimisation (with a 
random element) to balance for the number 
of key symptoms (dysuria, frequency, and/
or urgency) at presentation. Practice 
stratification was kept confidential to help 
with allocation concealment. 
Clinical examination
Using a 7-point scale — from 0 (not affected) 
to 6 (as bad as it could be) — clinicians 
recorded the presence and severity of 
baseline clinical features, including: 
• daytime frequency (of urination);
• urgency;
• burning or pain when passing urine 
(dysuria);
• night-time frequency;
• feeling generally unwell;
• abdominal pain;
• smelly urine;
• restricted activities;
• pain in the side (costovertebral angle 
tenderness); 
• fever; and
• blood in urine.
The scale was similar to previously used 
instruments22 and was part of the symptom 
diary that participants were asked to 
complete each day. Clinicians also recorded 
the diagnostic tests (that is, urine dipstick 
testing) carried out, antibiotics prescribed, 
and planned follow-up.
Sample collection
Participants were asked to provide a urine 
and optional stool sample on the day of 
recruitment. Urine samples were collected 
using the Peezy midstream urine collection 
kit. For participants randomised to the 
intervention, urine samples were split: a 
portion was earmarked for the intervention 
test and the rest was sent for culture, in 
containers with boric acid, to local network 
laboratories using routine clinical sample 
transport arrangements (Spain and the 
How this fits in
Although the analytic performance of point-
of-care (POC) urine culture tests has been 
investigated, its effect on antibiotic use that 
is congruent with laboratory culture results 
has not been evaluated in a randomised 
controlled trial. POC urine culture, used 
mainly for adjusting empirical antibiotic 
prescribing decisions for uncomplicated 
urinary tract infection in primary care, 
did not lead to an increase in concordant 
antibiotic prescribing or improve patient 
outcomes, and was not cost-effective.
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Netherlands) or to a central laboratory 
by post (England and Wales). Participants 
were asked to return stool samples by 
post to their designated local laboratory 
within 24 hours of collection and to provide 
further urine and stool samples at day 14. 
Stool samples were obtained to estimate 
the effect on resistance in faecal flora. 
Participants were asked to provide a stool 
sample at baseline and at 2 weeks. 
Trial intervention
Clinicians were asked to use the 
Flexicult™ POCT urine culture to guide the 
management of participants randomised 
to the intervention, but it was for them to 
decide or negotiate with the patient on 
how best to use the test. For example, they 
could avoid empirical prescribing and use 
the test to: 
• determine whether, and what antibiotic 
class, to prescribe the following day;
• prescribe empirically and use the test 
to aid in a next-day review of the initial 
prescribing decision; or 
• provide a delayed antibiotics prescription 
and use the test to guide use of the 
delayed prescription. 
Management decisions were recorded 
after reading the test in the intervention 
arm. 
Flexicult POCT urine culture involves fresh 
urine being poured onto a chromogenic agar 
plate, which is then incubated at 35–37°C 
overnight in a small desktop incubator 
in the practice; the results are reviewed 
18–24 hours later. The chromogenic agar 
plate is sub-divided into six segments: the 
largest allows for the identification of species 
(by colour of colonies) and bacterial growth; 
the other five contain agar impregnated 
with antibiotics and are used to assess 
antibiotic susceptibility (Figure 1). Clinicians 
were provided with face-to-face training, a 
country-specific Flexicult brochure, and a 
poster to aid interpretation of the results. 
Further training resources were available 
online at www.POETIC-study.co.uk.
When reading the Flexicult urine culture 
test, clinicians recorded: 
• bacterial growth, based on the number of 
colonies;
• bacterial identification, based on the 
colour of colonies; and 
• antibiotic resistance of the pure or 
predominant organisms, based on the 
presence of bacterial growth in the 
antibiotic sections. 
Antibiotic susceptibility was only recorded 
if growth was ≥103 colony-forming units 
per millilitre (CFU/mL) in the large plate 
section.
Standard care
Patients randomised to the standard-care 
arm received care informed by national 
Amoxicillin/
clavulanate
(16/8 mg/L)
Nitrofurantoin (64 mg/L) Ciprofloxacin (0.75 mg/L)
Trimethoprim (3 mg/L)
Spain:a Fosfomycin (32 mg/L)
Quantification section
Cephalothin (16 mg/L)
Spain:a Cefuroxime (8 mg/L)
NL:b Amoxicillin (8 mg/L)
Figure 1. The UK Flexicult SSI-Urinary Kit.
aIn Spain, fosfomycin was used instead of 
trimethoprim, and cefuroxime instead of cephalothin. 
bIn the Netherlands, amoxicillin was used instead of 
cephalothin.
Yes
Microbiologically
confirmed UTI
Yes No
Antibiotic
consumed on day 3
Yes
Sensitive to
antibiotic
No
Antibiotic
consumed on day 3
No
No
Yes
Appropriate antibiotic usage
Inappropriate antibiotic usage
Figure 2. Decision tree to ascertain whether antibiotic 
prescribing is concordant or discordant.
UTI = urinary tract infection.
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guidelines; clinicians received a summary of 
relevant national treatment guidelines.
Participant follow-up
All participants were asked to complete a 
2-week daily symptom diary, which covered 
medical history and included the Patient 
Enablement Instrument.23 On each of the 
14 days, participants were asked to rate the 
presence and severity of symptoms (using 
the same scale as at baseline) and record 
any antibiotic use. On day 14, they were 
asked to record all resource use associated 
with UTI and time off work. Non-responders 
were reminded by telephone and given the 
opportunity to complete minimum data set 
questions, which consisted of a question 
about the day on which the woman felt she 
had recovered and about antibiotic use.
At 3 months, the primary care medical 
records were examined for re-consultations 
with primary and secondary care, recurrences 
of UTI, and further antibiotic use. 
Microbiological procedures
Local laboratories were provided with a 
POETIC microbiology manual and standard 
operating procedures.21 
UTI definition 
The definition of a UTI used by the laboratory 
serving the participating clinicians was 
used to compare results of the point-of-
care (POC) Flexicult test, because the POCT 
aimed to give the same information as the 
laboratory-based test, only quicker. In Wales, 
England, and Spain, the definition of a UTI 
on laboratory culture was ≥105 CFU/ mL of a 
pure/predominant recognised uropathogen 
(where predominant was defined as a 
≥103 CFU/mL difference between the first- 
and second-highest bacterial growths); in the 
Netherlands, the definition was 104 CFU/mL 
growth of a pure/predominant recognised 
uropathogen.
Statistical considerations
Sample size calculation. A sample of 460 
patients (230 for each arm) for final analysis 
was required (significance level α 0.05, 
statistical power [1–β] 0.90) to allow for an 
increase in concordant antibiotic usage from 
55% in the standard-care arm to 70% in the 
intervention arm. This was inflated to 614 to 
allow for a 25% loss to follow-up. The analysis 
took clustering by practice into account. 
Primary outcome. The primary outcome was 
concordant antibiotic use, defined as: 
• consumption of an antibiotic on day 3 (or 
day 1 or day 2 for fosfomycin), for which a 
pathogen considered to be causing a UTI 
isolated in a laboratory was sensitive in 
vitro; or
• no antibiotic use by females who did 
not have a UTI on laboratory culture 
(Figure 2). 
Sensitivity analyses were undertaken 
using the primary outcome calculated 
using the Flexicult plate results and initial 
antibiotic prescribing. 
Secondary outcomes. Secondary outcomes, 
also defined at the outset in the protocol, 
comprised: 
• initial antibiotic prescription (that is, on 
day 1) and at any point during the 2-week 
follow-up period;
• dose and duration of antibiotic;
• antibiotic consumption;
• adherence to national prescribing 
guidelines;
• recovery (duration of symptoms and 
symptom burden);22,24
• antibiotic resistance in urine and stool 
samples at 2 weeks;
• patient enablement;23
• re-consultation; 
• recurrence of UTI;
• hospitalisation;
• direct/indirect costs (within a 3-month 
period); and 
• cost-effectiveness.
Statistical analysis
Analyses of primary and secondary 
outcomes were based on a modified 
intention-to-treat (ITT) population. A 
sensitivity analysis was conducted using 
multiple imputations to account for missing 
outcome data (supplementary material 
available from the authors on request). 
Multilevel regression models were used 
to account for clustering of patients 
within practices. Country (England, the 
Netherlands, Spain, and Wales), number 
of key symptoms (one, two, or three), and 
stratifying and balancing variables were 
included as covariates in all models.
Logistic, linear, or futility (survival) 
analyses were undertaken as appropriate. 
Urinary symptom burden was calculated 
using the area under the curve (AUC) of the 
total symptom score for urgency, daytime 
frequency, and night-time frequency on 
each day. Due to its distribution, the AUC 
symptom burden was natural logged, and 
patient enablement was dichotomised for 
analysis. 
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Wales n = 219 (33.5%)
England n = 234 (35.8%)
Spain n = 166 (25.4%)
the Netherlands n = 35 (5.3%)
Flexicult n = 329
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England n = 117
Spain n = 86
the Netherlands
n = 17
Standard care n = 325
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n = 103
Wales n = 27
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the Netherlands n = 18
Positive samples
n = 117
Wales n = 36
England n = 34
Spain n = 33
the Netherlands n = 14
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Wales n = 7
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the Netherlands n = 0
Positive samples
n = 20
Wales n = 4
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Analysis of primary
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the Netherlands n = 6
Analysis of primary
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Wales n = 80
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Figure 3. CONSORT flow diagram. aData for derivation of primary outcome analysis required each participant to have 2-week diary and urinalysis data available. CRF = case 
report form. FU = follow-up.
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Health economic evaluation
The authors aimed to assess mean total 
cost (including the cost of the POCT) per 
unit increase in concordant antibiotic 
prescribing.21 ITT analysis was used to 
determine the difference in resource use 
and difference in effectiveness between 
the intervention and control groups. Where 
cost data were skewed, 10 000 replications 
and bias-corrected, non-parametric, 
bootstrap methods were used to determine 
95% CIs; analysis accounted for cluster 
effect.25 A cost-effectiveness acceptability 
curve was used to show the probability 
of the intervention having an incremental 
cost-effectiveness ratio below a range of 
acceptability thresholds.26 
RESULTS
Participants were recruited between July 
2013 and August 2014, with 329 randomised 
to the intervention (Flexicult) arm and 325 to 
standard care. Baseline data were available 
for 324 in the intervention arm and 319 
in the standard-care arm. The authors 
ascertained initial antibiotic prescribing 
for 100% of participants, obtained primary 
outcome data for 252 (76.6%) and 245 
(75.4%) respectively (Figure 3), and also had 
3-month follow-up data for 98.8%. 
There were no important measured 
differences between those with and without 
primary outcome data (further information 
available from the authors on request) and 
the two arms were well balanced in terms 
of baseline variables. Frequency, urgency, 
and dysuria were the symptoms most often 
reported by patients as being a problem; 
those reported as being a problem the least 
number of times were fever, blood in the 
Table 1. Participant baseline data on presentation by management allocation, intervention (n = 324) versus 
standard care (n = 319)
  Flexicult Standard care Overall
 na Mean (SD)b Mean (SD)b Mean (SD)b,c
Age, years 643 47.6 (22.5) 47.6 (22.4) 47.6 (27.6)
Temperature, °C 613 36.6 (0.95) 36.6 (0.85) 36.6 (1.18)
	 	 n	(%)	 n	(%)	 n	(%)
Symptoms reported by patient as a problemd 
 Daytime frequency (of urination) 643 294 (90.7) 295 (92.5) 589 (91.6) 
 Urgency 643 288 (88.9) 286 (89.7) 574 (89.3) 
 Burning or pain (dysuria) 642 268 (83.0)  252 (79.0) 520 (81.0) 
 Night-time frequency 643 261 (80.6) 260 (81.5) 521 (81.0) 
 Feeling generally unwell 637 231 (72.0) 220 (69.6) 451 (70.8) 
 Abdominal pain 641 209 (64.7)  203 (63.8) 412 (64.3) 
 Smelly urine 642 177 (54.6) 190 (59.7) 367 (57.2) 
 Restricted activities 643 171 (52.8) 163 (51.1) 334 (51.9) 
 Pain in the side 642 155 (48.0) 142 (44.5) 297 (46.3) 
 Fever 638 92 (28.8)  93 (29.2) 185 (29.0) 
 Blood in urine 641 88 (27.2) 72 (22.6) 160 (25.0)
Number of symptoms (dysuria, frequency, urgency)e 643 
 1  34 (10.5) 29 (9.1) 63 (9.8) 
 2  96 (29.6) 97 (30.4) 193 (30.0) 
 3  194 (59.9) 193 (60.5) 387 (60.2)
Microbiologically confirmed UTI 612 103 (33.4) 117 (38.5) 220 (35.9)
UTIs with causative organism resistant to any 220 16 (15.5)  24 (20.5) 40 (18.2)  
first-line antibiotic (nitrofurantoin, trimethoprim,     
or fosfomycin)
UTI in the previous 12 months 431 
 0  67 (31.3) 70 (32.3) 137 (31.8) 
 1–2  88 (41.1) 85 (39.2) 173 (40.1) 
 ≥3   52 (24.3) 58 (26.7) 110 (25.5) 
 Don’t know  7 (3.3) 4 (1.8) 11 (2.6)
aThese represent the overall N. bInflated for clustering by practice. cThe overall SDs for age and temperature are substantially higher than those of either arm due to the nature 
of the inflation calculation; given that this is an individually randomised trial, the cluster size is, essentially, doubled for the overall calculation. dSymptoms reported as a problem 
include all categories from ‘Very little problem’ (score of 1) to ‘As bad as it could be’ (score of 6). eBalancing variable in randomisation. SD = standard deviation. UTI = urinary tract 
infection.
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urine and feeling generally unwell (Table 1). 
Approximately one-third (220/612, 35.9%) 
of responders had a microbiologically 
confirmed UTI (Table 1). 
More participants in the standard-care 
arm reported concordant antibiotic use at 
day 3 than in the intervention arm (108/245 
[44.1%] versus 99/252 [39.3%]), although 
this was not statistically significant (OR 
0.84, 95% confidence interval [CI] = 0.58 
to 1.20) (Table 2). The main driver of 
discordant usage was use of antibiotics with 
Table 2. Comparison of intervention versus standard care for primary and secondary outcomesa
   Flexicult  Standard care 
  Category n (%)  n (%) Odds ratio 95% CI ICC
	 	 	 	Primary	outcome
Concordant	antibiotic	usage
 
Yes
 UTI + antibiotic + sensitive 58 (23.0)  67 (27.3)
 0.84 0.58 to 1.20 0.02
 
  No UTI + no antibiotic 41 (16.3)  41 (16.7) 
  Total 99 (39.3)  108 (44.1)
 
No
 UTI + antibiotic + resistant 5 (2.0)  10 (4.1) 
  UTI + No antibiotic 12 (4.8)  17 (6.9) 
  No UTI + antibiotic 136 (54.0)  110 (44.9) 
  Total 153 (60.7)  137 (55.9)
                                                                      Secondary	analyses	of	primary	outcome
Concordant antibiotic usage sensitivity: Flexicultb   99 (39.4)  108 (44.1) 0.84 0.58 to 1.20 n/a
Concordant antibiotic prescribing sensitivity:    98 (33.1)  114 (38.5) 0.79 0.57 to 1.11 0.01 
initial consultationc
    Secondary	outcomes
Antibiotic prescribing at initial consultation   267 (82.4)  282 (88.4) 0.56 0.35 to 0.88 0.46
Prescribed to guidelines at initial consultationd   156 (58.9)  166 (59.5) 0.99 0.67 to 1.45 0.67
  UTI-specific and 1–3 days 182 (69.2)  185 (67.8) (ref) n/a 
Drug	type  UTI-specific and >3 days 50 (19.0)  57 (20.9) 1.15 0.71 to 1.87 
and	duratione  Broad spectrum and 1–3 days 0 (0.0)  0 (0.0) (empty)  
  Broad spectrum and >3 days 31 (11.8)  31 (11.4) 1.00 0.58 to 1.75
Patient enablement (dichotomised)   171 (70.1)  177 (69.7) 0.99 0.66 to 1.48 n/a
Antibiotic consumed (day 3)   217 (79.2)  200 (76.6) 1.24 0.81 to 1.89 0.24
Antibiotic consumed (during 2 weeks)   234 (85.1)  217 (81.6) 1.38 0.87 to 2.19 0.33
New antibiotic prescribed (within 2 weeks)   33 (10.3)  30 (9.7) 1.11 0.65 to 1.89 n/a
Re-consultation (within 2 weeks)   41 (12.9)  41 (13.2) 0.99 0.62 to 1.60 n/a
Hospital stay (within 2 weeks)   3 (0.9)  4 (1.3)  Numbers too small for analysis
Microbiologically confirmed UTI (at 2 weeks)   20 (8.7)  20 (9.2) 0.94 0.49 to 1.81 n/a
  Ciprofloxacin 33 (22.4)  34 (24.5) 0.96 0.54 to 1.71 0.396 
Stool	sample	resistance  Extended-spectrum beta-lactamases 12 (8.2)  8 (5.8) 1.35 0.53 to 3.46 n/a 
(at	2	weeks)  Gentamicin 16 (10.9)  9 (6.5) 1.75 0.74 to 4.42 n/a 
  Carbapenem 0 (0.0)  1 (0.7)  Numbers too small for analysis 
Recurrence (within 3 months)   54 (17.0)  69 (22.3) 0.72 0.48 to 1.07 n/a
	 	 	 Median	(IQR)	 	 Median	(IQR)	 HR	 95%	CI	 ICC
Duration of all symptoms   8.0 (5.0–14.0)  8.0 (5.0–14.0) 1.02 0.83 to 1.25 n/a
Duration of moderately bad symptoms   4.0 (2.0–6.0)  4.0 (2.0–6.0) 0.98 0.82 to 1.17 n/a
	 	 	 Mean	(SD)	 	 Mean	(SD)	 MD	 95%	CI	 ICC
Overall urinary symptom burden (AUC over 2 weeks)f  39.5 (36.56)  38.2 (34.56) 0.99 0.84 to 1.19 n/a
aFor these analyses, the denominator depends on the amount of relevant data available, which is not always 324 and 319 for Flexicult (intervention) and Standard Care respectively. 
As stated in the results section, the denominators for this analysis are 252 and 245 for Flexicult (intervention) and Standard Care respectively. bUTI and antibiotic resistance defined 
by the clinician’s reading of the Flexicult plate. cAntibiotic prescribed at initial consultation or, if available, the antibiotic prescribed after reading the Flexicult plate. dPrescribed to 
guidelines (England and Wales: trimethoprim, 3 days; nitrofurantoin, 3 days; Spain: fosfomycin, 1 day; nitrofurantoin, 7 days; the Netherlands: nitrofurantoin, 5 days; fosfomycin, 
1 day; trimethoprim, 3 days) based on prescription made at the initial consultation. This excludes those who did not receive a prescription and those for which the prescribed drug is 
unknown. eAs a multinomial model, relative risk ratios, rather than odds ratios, are given. fEffect/95% CI are back-transformed from a natural log transformation. AUC = area under 
the curve. ICC = intracluster correlation coefficient. HR = hazard ratio. IQR = interquartile range. n/a = not applicable. MD = mean difference. SD = standard deviation. UTI = urinary 
tract infection.
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no laboratory microbiological confirmation 
of UTI (110/245 [44.9%] patients in the 
standard-care arm and 136/252 [54.0%] 
patients in the intervention arm) (data 
not shown). Only 10/245 (4.1%) and 5/252 
(2.0%) in the standard-care and intervention 
arms respectively received an antibiotic to 
which the infecting organism was resistant 
(Table 2). Sensitivity analyses, including full 
ITT analyses using multiple imputations, did 
not alter the conclusions (Table 2, additional 
information available from the authors on 
request).
Secondary outcomes (Table 2) include 
fewer females who were prescribed 
antibiotics at initial consultation in the 
intervention arm than in the standard-
care arm (267/324 [82.4%] versus 282/319 
[88.4%], OR 0.56, 95% CI = 0.35 to 0.88), 
but no differences in: antibiotic prescribing 
at any point; antibiotic resistance and 
consumption; adherence to national 
prescribing guidelines; patient enablement; 
symptom severity or duration; recurrence; 
re-consultation; hospitalisation; or 
resistance in urine and stool samples at 
2 weeks.
Clinicians reported using the Flexicult 
POC test for 313/324 (96.6%) of participants 
randomised to the intervention (data not 
shown). They indicated that they had 
contacted 176/303 (58.1%) females in 
response to the test result (data not shown) 
and that it had changed management for 
190/301 (63.1%): 14 (7.4%) of those with 
a change of management were advised 
not to start taking an antibiotic; 10 (5.3%) 
were advised to stop taking an antibiotic 
they had already started; 29 (15.3%) to start 
taking an antibiotic; 63 (33.2%) to keep 
taking an antibiotic that was prescribed 
at the baseline visit; and 74 (38.9%) were 
prescribed a new antibiotic (Table 3). There 
were two reports of Flexicult use in the 
standard-care arm; these participants were 
not excluded from all analyses.
It took an average of 9 minutes to prepare 
the Flexicult test, 6 minutes to obtain and 
record the results, and 7 minutes to discuss 
the results with the patient. The total cost 
per person of the intervention, including 
the cost of the POCT, was £48 (England 
and Wales), €56 (the Netherlands), and €32 
(Spain); the delivery costs contributed to 
nearly 90% of the total cost. At day 3, the 
average cost of antibiotic prescribing was 
similar between the two groups. There were 
no differences in any other healthcare costs 
by day 3, patient-borne costs at 14 days, or 
healthcare resource use at 3 months. 
A cost-effectiveness ratio showed that 
the intervention is never cost saving; in 
addition, it is cost-effective only in limited 
cases and against a high willingness to 
pay for it. However, the cost of antibiotic 
resistance is not included in estimates.27
DISCUSSION
Summary
In this clinical and cost-effectiveness 
randomised controlled trial of POCT urine 
culture for uncomplicated UTI in females in 
primary care, it was found that marginally 
fewer antibiotics were prescribed at the 
initial consultation for patients in the 
POCT arm. Clinicians indicated that they 
had contacted nearly 60% of patients in 
response to the test, that it had changed 
their management in nearly two-thirds 
of cases, and they had prescribed a new 
antibiotic in just over one-third of those for 
whom they had a test result. However, they 
generally prescribed antibiotics empirically 
at the initial consultation without waiting 
for the test result, and seldom withdrew 
antibiotic treatment that had already been 
Table 3. Clinician advice about antibiotic treatment in response to Flexicult result
 Did the Flexicult result indicate that a UTI was present?
   No Yes Missing Total
   n (%) n (%) n (%) n (%)
‘Was patient’s management changed  No 78 (38.8) 31 (33.0) 2 (33.3) 111 (36.9) 
in response to the test result?’ Yes 123 (61.2) 63 (67.0) 4 (66.7) 190 (63.1) 
 Total	 201	(100.0)	 94	(100.0)	 6	(100.0)	 301	(100.0)
 No antibiotic needed 14 (11.4) 0 (0.0) 0 (0.0) 14 (7.4) 
 /don’t start antibiotic 
 Stop taking antibiotic 10 (8.1) 0 (0.0) 0 (0.0) 10 (5.3) 
Change of management Start taking antibiotic 16 (13.0) 11 (17.5) 2 (50.0) 29 (15.3) 
 Continue with antibiotic 35 (28.5) 27 (42.9) 1 (25.0) 63 (33.2) 
 New antibiotic prescribed 48 (39.0) 25 (39.7) 1 (25.0) 74 (38.9) 
 Total	 123	(100.0)	 63	(100.0)	 4	(100.0)	 190	(100.0)
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started when the test indicated no UTI. 
Despite the test changing clinicians’ 
advice and decisions about antibiotic 
prescribing for UTI, the authors found no 
evidence of any difference in the primary 
outcome of patient-reported antibiotic 
use that was concordant with laboratory 
(as opposed to the POCT) culture results. 
Patient-reported recovery was not changed 
by test use, despite the additional costs of 
the test.
The main driver of discordant antibiotic 
use for females was antibiotic consumption 
without a microbiologically confirmed UTI, 
rather than use of antibiotics to which the 
UTI pathogen was not susceptible.
Strengths and limitations 
Clinicians could decide or discuss with the 
patient about how best to use the test, 
for example, to aid in a next-day review of 
an initial antibiotic prescribing decision; 
to guide starting a delayed antibiotic 
prescription; or to determine whether, 
and what antibiotic class, to prescribe the 
following day. Flexicult is a POC test, in 
that it is performed where the patient is 
receiving care and outside of the clinical 
laboratory setting. However, even though 
the results are available within 24 hours 
— which is generally far quicker than 
laboratory culture results — it is not a rapid 
test. As such, it can be used in a number of 
ways; approximately 30% of the test results 
led to treatment changes in this study. 
This large, pragmatic trial involved 
multiple sites in four countries, recruited 
to target. It achieved high ascertainment 
rates, so external validity should be high. 
In addition, there were no meaningful 
differences in baseline characteristics 
between those for whom the authors did, 
and did not, ascertain the primary outcome. 
Clinicians were not able to reliably keep logs 
of eligible patients who were not recruited, 
so estimating the proportion of potentially 
eligible participants who were invited to 
participate is not possible. Not all clinicians 
in participating practices were part of the 
study and many who were did not work full 
time and were not available to recruit on 
each day they worked.
Patient-reported antibiotic consumption 
was used in order to take into account: 
adherence; prescribing from other sources, 
such as use of leftover antibiotics; and 
prescribing by out-of-hours and other 
emergency care clinicians. However, 
information was retrieved on further 
antibiotic prescriptions and additional 
consultations in primary care over 3 months 
after the initial consultation for almost all 
patients. The authors found little evidence 
of contamination — namely, use of POCT 
in the standard-care arm — and clinicians 
reported using the POC test in 96.6% of 
those randomised to the intervention. 
This was an open trial of the change of a 
POC test on clinicians’ prescribing behaviour 
and, ultimately, on patients’ adherence to 
those prescribing decisions. Open studies 
capture the changing of clinicians’ and 
patients’ expectations of interventions on 
behaviour, which is important to ascertain 
an accurate estimate of healthcare costs. 
Delivering the intervention took a median 
of 17 minutes (results were discussed with 
patients in about two-thirds of cases); this 
constitutes a substantial opportunity cost 
of alternative use of health professionals’ 
time,28 but may reduce once greater 
familiarity is established. POCT urine culture 
was, therefore, not cost-effective in primary 
care when used mainly to guide changes to 
initial antibiotic prescribing decisions; this 
was largely because antibiotic prescribing 
decisions were not delayed until results 
were known, and antibiotics were not always 
stopped when there was no evidence of a 
UTI on POCT. 
Comparison with existing literature
Although all participants were presenting 
with symptoms of uncomplicated UTI, only 
35.9% had a UTI confirmed on culture. This 
is similar to the 25–50% culture positivity 
rates found in observational studies.10–13 
Possible explanations include UTIs caused 
by pathogens that are not identifiable on 
routine urine culture, problems with sample 
transportation, or contamination masking 
true UTIs. Any of these possibilities may 
have affected results according to the 
authors’ primary outcome. Although 
routine laboratory urine culture provides 
the diagnostic information that clinicians 
would usually obtain if they chose to submit 
a sample, it is not a perfect reference 
standard, as routine culture may produce 
inconsistent results and vary between 
laboratories.29 
In a separate analysis, the authors 
examined clinicians’ interpretations of 
the Flexicult urine culture results in this 
study, and found they overestimated the 
proportion that was positive for UTI when 
compared with the results of laboratory 
culture of urine from the same patient.30 
Observing some growth on a culture plate 
from fresh urine from a patient who is 
symptomatic may have made clinicians 
reluctant to stop antibiotics, despite the 
level of growth on the POCT culture not 
technically meeting the threshold for a 
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UTI. It is also not clear whether routine 
laboratory culture with associated delays 
in transport and processing, or more rapid 
POC culture, give a more valid answer. 
The authors have previously examined 
the analytic performance of the Flexicult 
test using routinely submitted urine 
samples,31 and the analytic performance 
of other POCT culture approaches have 
also been assessed.19,32–34 However, it 
was not possible to identify previous 
evaluations of intervention implementation 
to improve the management of UTI in 
terms of inappropriate antibiotic use, costs, 
resistance, and health outcomes. Holm et 
al have also found that POC culture was 
better at ruling in, rather than ruling out, a 
UTI diagnosis based on laboratory culture.34
Implications for research and practice
In test–treatment trials,4 patient outcomes 
are only likely to be affected if patients receive 
a valid test and appropriate diagnosis, 
management decisions are made, and 
treatment is implemented and adhered 
to. In interpreting the plates, clinicians 
may have assumed that low-threshold 
bacterial growth in females with symptoms 
suggestive of UTI justified antibiotic 
treatment and, therefore, refrained from 
adjusting it. Had clinicians prescribed or 
adjusted their initial prescriptions according 
to POCT urine culture results, and patients 
had changed their antibiotic consumption 
behaviour accordingly, the intervention may 
have been effective. This underlines the 
importance of paying attention to targeted 
behaviour-change strategies in conjunction 
with the introduction of new tests. 
The Flexicult POC test was not clinically 
or cost-effective when used mainly for 
adjusting antibiotic prescribing decisions 
for UTI after the test result became 
available. Given the low levels of antibiotic 
resistance identified in these systematically 
sampled patients with uncomplicated UTI, 
along with the challenges associated with 
stopping short courses of antibiotics when 
the patient is in the community, future 
research should focus on assessing the 
effect of culture-based POC tests (such as 
Flexicult) in the context of advising patients 
to delay prescribing until the results of the 
test are known. Symptomatic treatments 
offered at the point of consultation may 
improve the acceptability and uptake of this 
approach. 
Few POC tests have been subjected to 
rigorous, pragmatic clinical trials of cost-
effectiveness using a range of outcomes, 
including patient-orientated measures.2 
This study underlines the importance of 
conducting a rigorous, pragmatic trial 
of cost-effectiveness (and not, simply, of 
analytic performance) and evidence-based 
identification of the place of such tests in 
clinical pathways, before new diagnostic 
technologies are adapted into usual care. 
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